13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002026172
Total reported value
$791.3M
$791.3M
86 檔
10.5%
At the close of Q4 2024, Diadema Partners LP disclosed equity holdings valued at approximately $791.3M, spread across 86 reported holdings.
During Q4 2024, Diadema Partners LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including VRTX, XBI, ABBV) accounted for 10.5% of total reported equity market value during Q4 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 9.92% | -7.37% | EXIT | |
| 2 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 7.73% | — | — | |
| 3 | ABBV | Abbvie Inc | Stock-Healthcare | 7.62% | -0.89% | EXIT | |
| 4 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 6.60% | — | — | |
| 5 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 3.88% | +6.78% | NEW | |
| 6 | ACLXGBX | Arcellx Inc | Stock-Other | 3.62% | — | — | |
| 7 | CRSP | CRISPR Therapeutics AG | Stock-Healthcare | 3.22% | -0.86% | EXIT | |
| 8 | TGTX | Tg Therapeutics Inc | Stock-Healthcare | 3.20% | -0.64% | — | |
| 9 | INSM | Insmed Inc | Stock-Healthcare | 3.15% | — | — | |
| 10 | TEVA | Teva Pharmaceutical-sp Adr | Stock-Healthcare | 2.86% | — | — | |
| 11 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 2.85% | -0.13% | EXIT | |
| 12 | 2655787D | Blueprint Medicines CORP | Stock-Other | 2.40% | — | — | |
| 13 | HALO | Halozyme Therapeutics Inc | Stock-Healthcare | 2.05% | — | — | |
| 14 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 1.80% | — | — | |
| 15 | ANAB | Anaptysbio Inc | Stock-Other | 1.79% | — | — | |
| 16 | SRRK | Scholar Rock Holding CORP | Stock-Other | 1.78% | — | — | |
| 17 | AZNN | Astrazeneca Plc-spons Adr | Stock-Other | 1.69% | — | — | |
| 18 | KROS | Keros Therapeutics Inc | Stock-Other | 1.66% | — | — | |
| 19 | BHVN | Biohaven Ltd. | Stock-Other | 1.60% | +0.14% | — | |
| 20 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 1.57% | — | — | |
| 21 | CAPR | Capricor Therapeutics Inc | Stock-Other | 1.53% | -2.71% | — | |
| 22 | ASND | Ascendis Pharma A/S | Stock-Other | 1.49% | — | — | |
| 23 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 1.44% | — | — | |
| 24 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 1.43% | -0.31% | EXIT | |
| 25 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 1.37% | — | — | |
| 26 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 1.18% | -1.08% | EXIT | |
| 27 | CLDX | Celldex Therapeutics Inc | Stock-Other | 1.08% | +0.64% | NEW | |
| 28 | RLAY | Relay Therapeutics Inc | Stock-Other | 1.07% | +0.55% | NEW | |
| 29 | RCUS | Arcus Biosciences Inc | Stock-Other | 1.06% | +0.48% | — | |
| 30 | APGE | Apogee Therapeutics Inc | Stock-Other | 0.98% | -3.19% | EXIT | |
| 31 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 0.95% | — | — | |
| 32 | RXRX | Recursion Pharmaceuticals-a | Stock-Healthcare | 0.87% | — | — | |
| 33 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 0.78% | -1.76% | EXIT | |
| 34 | QURE | uniQure N.V. | Stock-Other | 0.76% | +1.50% | — | |
| 35 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 0.74% | — | — | |
| 36 | ALT | Altimmune Inc | Stock-Other | 0.62% | — | — | |
| 37 | REPL | Replimune Group Inc | Stock-Other | 0.59% | +0.68% | — | |
| 38 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 0.57% | — | — | |
| 39 | VTGN | Vistagen Therapeutics Inc | Stock-Other | 0.56% | -0.01% | — | |
| 40 | DNLI | Denali Therapeutics Inc | Stock-Other | 0.52% | — | — | |
| 41 | NUVL | Nuvalent Inc-a | Stock-Other | 0.49% | — | — | |
| 42 | EOLS | Evolus Inc | Stock-Other | 0.46% | +0.09% | — | |
| 43 | BNTX | Biontech Se-adr | Stock-Other | 0.43% | +1.18% | NEW | |
| 44 | VRDN | Viridian Therapeutics Inc | Stock-Other | 0.41% | +0.23% | NEW | |
| 45 | AM6 | Amicus Therapeutics Inc | Stock-Other | 0.40% | — | — | |
| 46 | JANX | Janux Therapeutics Inc | Stock-Other | 0.40% | -0.07% | EXIT | |
| 47 | OCUL | Ocular Therapeutix Inc | Stock-Other | 0.38% | — | — | |
| 48 | FLNA | Filana Therapeutics Inc | Stock-Other | 0.38% | — | — | |
| 49 | NMRA | Neumora Therapeutics Inc | Stock-Other | 0.37% | — | — | |
| 50 | PCVX | Vaxcyte Inc | Stock-Other | 0.35% | +0.31% | — |
According to official SEC Form 13F filings, Diadema Partners LP reported a total U.S. public equity portfolio value of $791.3M across 86 disclosed positions in Q4 2024.
During Q4 2024, Diadema Partners LP's top holdings by market value included VRTX (9.9%)、XBI (7.7%)、ABBV (7.6%). The largest single position, VRTX, represented 9.9% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In Q4 2024, Diadema Partners LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.